CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
Submission of Matters to a Vote of Security Holders. |
| (a) |
The Annual Meeting of the Cyclacel Pharmaceuticals, Inc. (the “Company”) was held on May 31, 2018 (the “Annual Meeting”). |
| (b) |
Proposals Submitted to the Company’s Stockholders |
The following proposals were submitted to the Company’s stockholders and voted upon at the Annual Meeting: (i) the reelection of two Class 3 directors to the Company’s Board of Directors, (ii) the ratification of the selection of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2018 and (iii) the approval of the Company’s 2018 Equity Incentive Plan.
| (i) |
Votes of the stockholders regarding the election of the Class 3 director nominees were as follows: |
| VotesFor |
Votes Withheld |
Broker Non-Votes |
| Paul McBarron |
961,255 |
116,488 |
6,530,135 |
| Dr. Christopher Henney |
963,562 |
114,181 |
6,530,135 |
Based on the votes set forth above, Paul McBarron and Dr. Christopher Henney were duly reelected as Class 3 directors of the Company to serve until the 2021 annual meeting of stockholders or until their respective successors are elected and qualified or until their earlier resignation or removal.
| (ii) |
Votes of the stockholders regarding the ratification of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2018 were as follows: |
| VotesFor |
Votes Against |
Abstentions |
Broker Non-Votes |
| 7,131,920 |
248,503 |
227,455 |
|
Based on the votes set forth above, the selection of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2018 was ratified.
| (iii) |
Votes of the stockholders regarding the approval of the Company’s 2018 Equity Incentive Plan were as follows: |
| VotesFor |
Votes Against |
Abstentions |
Broker Non-Votes |
| 851,220 |
175,229 |
51,294 |
6,530,135 |
Based on the votes set forth above, the proposal to approve the Company’s 2018 Equity Incentive Plan was approved.
| Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
Cyclacel Pharmaceuticals, Inc. ExhibitEX-10.1 2 tv495639_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CYCLACEL PHARMACEUTICALS,…To view the full exhibit click here
About CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC)
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.